- Report
- March 2024
- 192 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- October 2023
- 190 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- March 2024
- 199 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- November 2023
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- February 2024
- 186 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Drug Pipelines
- April 2024
- 190 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Report
- January 2023
- 315 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- December 2022
- 363 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- October 2022
- 640 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- April 2021
- 260 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- March 2021
- 397 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- August 2019
- 580 Pages
Global
From €3860EUR$3,999USD£3,311GBP
- Report
- July 2019
- 800 Pages
Global
From €4342EUR$4,499USD£3,725GBP
- Report
- August 2022
- 1180 Pages
Global
From €5694EUR$5,899USD£4,884GBP
- Report
- July 2019
- 21 Pages
Global
From €603EUR$625USD£517GBP
€1206EUR$1,250USD£1,035GBP
- Report
- April 2024
- 175 Pages
From €4826EUR$5,000USD£4,140GBP
- Report
- October 2022
- 118 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma.
Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more